← Back to Screener
Natera, Inc. Common Stock (NTRA)
Price$215.31
Value ScoreF
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-17.77%
Price vs S&P 500 (4W)10.86%
VGM Score53.15
Market Capitalization$30.84B
All Metrics
P/CF (Annual)143.22x
Book Value / Share (Quarterly)$12.43
P/TBV (Annual)23.67x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)41.14%
Cash Flow / Share (Quarterly)$0.50
Price vs S&P 500 (YTD)-14.17%
Gross Margin (TTM)65.07%
Net Profit Margin (TTM)-9.05%
EPS (TTM)$-1.64
10-Day Avg Trading Volume1.44M
EPS Excl Extra (TTM)$-1.64
Revenue Growth (5Y)42.61%
EPS (Annual)$-1.52
ROI (Annual)-11.61%
Gross Margin (Annual)64.75%
Net Profit Margin (5Y Avg)-40.52%
Cash / Share (Quarterly)$7.62
Revenue Growth QoQ (YoY)38.82%
ROA (Last FY)-8.68%
Revenue Growth TTM (YoY)36.59%
EBITD / Share (TTM)$-2.14
ROE (5Y Avg)-46.95%
Operating Margin (TTM)-12.97%
Cash Flow / Share (Annual)$0.54
P/B Ratio17.38x
P/B Ratio (Quarterly)16.04x
Net Income / Employee (Annual)$-33,900
EV / Revenue (TTM)11.93x
Net Interest Coverage (TTM)-57.80x
ROA (TTM)-10.54%
EPS Incl Extra (Annual)$-1.52
Current Ratio (Annual)3.39x
Quick Ratio (Quarterly)2.70x
3-Month Avg Trading Volume1.36M
52-Week Price Return30.09%
EV / Free Cash Flow (Annual)391.89x
Revenue / Employee (TTM)$407,600
Tangible BV / Share (Quarterly)$9.86
P/S Ratio (Annual)13.37x
Asset Turnover (Annual)0.96x
52-Week High$256.36
Operating Margin (5Y Avg)-41.71%
EPS Excl Extra (Annual)$-1.52
CapEx CAGR (5Y)48.00%
Tangible BV CAGR (5Y)94.40%
26-Week Price Return-9.84%
Quick Ratio (Annual)3.11x
13-Week Price Return9.22%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)2.96x
Enterprise Value$29.83B
Revenue / Share Growth (5Y)28.43%
Asset Turnover (TTM)1.16x
Book Value / Share Growth (5Y)16.79%
Revenue / Employee (Annual)$375,900
Inventory Turnover (Annual)14.36x
Pretax Margin (Annual)-11.63%
Cash / Share (Annual)$7.70
3-Month Return Std Dev56.86%
Gross Margin (5Y Avg)52.81%
Net Income / Employee (TTM)$-36,900
ROE (Last FY)-12.16%
Net Interest Coverage (Annual)-39.23x
EPS Basic Excl Extra (Annual)$-1.52
P/FCF (TTM)431.21x
Receivables Turnover (TTM)6.80x
EV / Free Cash Flow (TTM)417.12x
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-1.64
Receivables Turnover (Annual)7.55x
ROI (TTM)-14.36%
P/S Ratio (TTM)12.33x
Pretax Margin (5Y Avg)-40.99%
Revenue / Share (Annual)$16.87
Tangible BV / Share (Annual)$9.58
Price vs S&P 500 (52W)5.72%
Year-to-Date Return-6.02%
5-Day Price Return-1.60%
EPS Normalized (Annual)$-1.52
ROA (5Y Avg)-25.55%
Net Profit Margin (Annual)-9.03%
Month-to-Date Return-3.61%
Cash Flow / Share (TTM)$-4.30
EBITD / Share (Annual)$-2.25
Operating Margin (Annual)-13.44%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)146.13x
ROI (5Y Avg)-32.86%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.64
P/TBV (Quarterly)20.23x
P/B Ratio (Annual)18.50x
Inventory Turnover (TTM)14.43x
Pretax Margin (TTM)-11.44%
Book Value / Share (Annual)$12.26
Price vs S&P 500 (13W)0.96%
Beta1.58x
P/FCF (Annual)405.13x
Revenue / Share (TTM)$17.67
ROE (TTM)-15.13%
52-Week Low$131.81
vGradeF
gGradeA
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.60est. -0.55
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.22
4.25
4.25
4.29
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NTRANatera, Inc. Common Stock | F | A | C | $215.31 |
| DGXQuest Diagnostics Inc. | C | D | C | $200.29 |
| LHLabcorp Holdings Inc. | C | D | C | $265.15 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| GHGuardant Health, Inc. Common Stock | F | A | B | $125.61 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.49 |
| CELCCelcuity Inc. Common Stock | — | — | C | $88.28 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $54.34 |
| VCYTVeracyte, Inc. | D | A | B | $48.73 |
| GRALGRAIL, Inc. Common Stock | D | A | C | $59.98 |
| FTREFortrea Holdings Inc. Common Stock | B | F | A | $16.08 |
About
Natera provides molecular diagnostic tests across reproductive health, oncology, and transplantation. Its main products include Panorama for non-invasive prenatal screening, Horizon for genetic carrier assessment, Signatera for circulating tumor DNA detection in cancer monitoring, and Prospera for organ transplant rejection assessment. The company leverages proprietary molecular and bioinformatics technology across these applications.